Trial Search Results

Ertugliflozin: Cardioprotective Effects on Epicardial Fat

The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Merck Sharp & Dohme LLC

Stanford Investigator(s):


  • Drug: Ertugliflozin
  • Drug: Glipizide


Early Phase 1


Inclusion Criteria:

   - patient at Stanford Cardiovascular Surgery clinic who is scheduled for cardiac bypass

   - history of Diabetes Mellitus Type 2 currently taking metformin or diet-controlled

Exclusion Criteria:

   - allergy or intolerance to interventional medication

   - currently taking any anti-diabetic medication other than metformin

Ages Eligible for Study

18 Years - 80 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Tracey McLaughlin, MD